Background
Materials and methods
Study design
Patient selection
Data collection
Statistical methods
Results
Physician characteristics
PFS diagnosis and patient characteristics at canakinumab initiation
Characteristics | Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | |||
---|---|---|---|---|---|---|---|
CAPS (N=59) | TRAPS (N=40) | HIDS/MKD (N=11) | FMF (N=42) | ||||
Age (years), mean (SD) | 21.7 (16.1) | 9.9 (4.5) | 31.9 (15.6) | 24.0 (18) | 21.4 (14.6) | 20.6 (9.8) | 18.2 (12.4) |
Female, n (%) | 63 (42.9) | 28 (41.2) | 35 (44.3) | 23 (39.0) | 18 (45.0) | 6 (54.5) | 19 (45.2) |
Body mass-index (for adults only; kg/m2), mean (SD) | 24.9 (5.6) [N=62] | - | 24.9 (5.6) [N=62] | 27.3 (5.9) [N=25] | 24.0 (6) [N=19] | 25.0 ± 4.8 [N=3] | 22.1 ± 2.9 [N=16] |
Race/ethnicity, n (%) | |||||||
White/Non-Hispanic | 103 (70.1) | 40 (58.8) | 63 (79.7) | 46 (78.0) | 29 (72.5) | 7 (63.6) | 25 (59.5) |
Hispanic | 23 (15.6) | 11 (16.2) | 12 (15.2) | 10 (16.9) | 6 (15.0) | 2 (18.2) | 6 (14.3) |
Asian/Pacific Islander | 8 (5.4) | 7 (10.3) | 1 (1.3) | 1 (1.7) | 1 (2.5) | 2 (18.2) | 4 (9.5) |
Black/Non-Hispanic | 7 (4.8) | 6 (8.8) | 1 (1.3) | 2 (3.4) | 4 (10.0) | 0 (0.0) | 1 (2.4) |
Other | 6 (4.1) | 4 (5.9) | 2 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (14.3) |
Insurance type, n (%) | |||||||
Commercial/private | 127 (86.4) | 59 (86.8) | 68 (86.1) | 51 (86.4) | 38 (95.0) | 9 (81.8) | 32 (76.2) |
Medicare | 15 (10.2) | 8 (11.8) | 7 (8.9) | 4 (6.8) | 2 (5.0) | 2 (18.2) | 8 (19.0) |
Medicaid | 7 (4.8) | 3 (4.4) | 4 (5.1) | 4 (6.8) | 2 (5.0) | 1 (9.1) | 1 (2.4) |
Military | 2 (1.4) | 2 (2.9) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
Other (i.e., Tricare) | 1 (0.7) | 0 (0.0) | 1 (1.3) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Primary medical specialty of the physician who prescribed canakinumab, n (%) | |||||||
Rheumatology | 48 (32.7) | 21 (30.9) | 27 (34.2) | 21 (35.6) | 10 (25.0) | 3 (27.3) | 14 (33.3) |
Dermatology | 46 (31.3) | 23 (33.8) | 23 (29.1) | 18 (30.5) | 14 (35.0) | 5 (45.5) | 11 (26.2) |
Immunology | 31 (21.1) | 18 (26.5) | 13 (16.5) | 14 (23.7) | 3 (7.5) | 3 (27.3) | 13 (31.0) |
Allergy | 22 (15.0) | 6 (8.8) | 16 (20.3) | 6 (10.2) | 13 (32.5) | 0 (0.0) | 4 (9.5) |
Primary subspecialty of the physician who prescribed canakinumab, n (%) | |||||||
Adult | 79 (53.7) | 23 (33.8) | 56 (70.9) | 33 (55.9) | 22 (55.0) | 3 (27.3) | 25 (59.5) |
Pediatrics | 68 (46.3) | 45 (66.2) | 23 (29.1) | 26 (44.1) | 18 (45.0) | 8 (72.7) | 17 (40.5) |
Disease duration (years) from first diagnosis to canakinumab initiation, mean (SD) | 5.2 (6.2) | 3.0 (2.5) | 7.1 (7.6) | 6.3 (6.7) | 3.9 (4.2) | 6.7 (8.5) | 4.7 (5.9) |
PFS severity, n (%) | |||||||
Mild | 33 (22.4) | 20 (29.4) | 13 (16.5) | 10 (16.9) | 12 (30) | 5 (45.5) | 6 (14.3) |
Moderate | 102 (69.4) | 45 (66.2) | 57 (72.2) | 44 (74.6) | 25 (62.5) | 6 (54.5) | 31 (73.8) |
Severe | 12 (8.2) | 3 (4.4) | 9 (11.4) | 5 (8.5) | 3 (7.5) | 0 (0.0) | 5 (11.9) |
Number of attacks/flares per year, n (%) | |||||||
<1 | 7 (4.8) | 5 (7.4) | 2 (2.5) | 5 (8.5) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
1-3 | 50 (34.0) | 19 (27.9) | 31 (39.2) | 20 (33.9) | 18 (45.0) | 4 (36.4) | 8 (19.0) |
4-6 | 64 (43.5) | 29 (42.6) | 35 (44.3) | 22 (37.3) | 15 (37.5) | 6 (54.5) | 24 (57.1) |
7-12 | 20 (13.6) | 11 (16.2) | 9 (11.4) | 8 (13.6) | 7 (17.5) | 1 (9.1) | 5 (11.9) |
>12 | 4 (2.7) | 2 (2.9) | 2 (2.5) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 3 (7.1) |
Unknown | 2 (1.4) | 2 (2.9) | 0 (0.0) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Average duration of attacks/flares, n (%) | |||||||
<1 day | 14 (9.5) | 7 (10.3) | 7 (8.9) | 4 (6.8) | 4 (10.0) | 3 (27.3) | 3 (7.1) |
1-3 days | 62 (42.2) | 29 (42.6) | 33 (41.8) | 29 (49.2) | 18 (45.0) | 2 (18.2) | 16 (38.1) |
4-7 days | 54 (36.7) | 23 (33.8) | 31 (39.2) | 18 (30.5) | 12 (30.0) | 6 (54.5) | 20 (47.6) |
>7 days | 10 (6.8) | 3 (4.4) | 7 (8.9) | 3 (5.1) | 6 (15.0) | 0 (0.0) | 1 (2.4) |
Unknown | 7 (4.8) | 6 (8.8) | 1 (1.3) | 5 (8.5) | 0 (0.0) | 0 (0.0) | 2 (4.8) |
PFS clinical manifestations at canakinumab initiation, n (%) | |||||||
Fever | 116 (78.9) | 57 (83.8) | 59 (74.7) | 41 (69.5) | 33 (82.5) | 8 (72.7) | 38 (90.5) |
Fatigue/malaise | 84 (57.1) | 36 (52.9) | 48 (60.8) | 30 (50.8) | 20 (50.0) | 8 (72.7) | 28 (66.7) |
Skin/cutaneous | 84 (57.1) | 36 (52.9) | 48 (60.8) | 30 (50.8) | 20 (50.0) | 8 (72.7) | 28 (66.7) |
Musculoskeletal | 74 (50.3) | 31 (45.6) | 43 (54.4) | 27 (45.8) | 19 (47.5) | 6 (54.5) | 26 (61.9) |
Gastrointestinal | 42 (28.6) | 22 (32.4) | 20 (25.3) | 12 (20.3) | 9 (22.5) | 6 (54.5) | 16 (38.1) |
Mood/behavior | 25 (17.0) | 12 (17.6) | 13 (16.5) | 13 (22.0) | 7 (17.5) | 0 (0.0) | 6 (14.3) |
Neurological | 9 (6.1) | 6 (8.8) | 3 (3.8) | 4 (6.8) | 2 (5.0) | 0 (0.0) | 3 (7.1) |
Ocular | 7 (4.8) | 2 (2.9) | 5 (6.3) | 4 (6.8) | 1 (2.5) | 1 (9.1) | 1 (2.4) |
Lymphoid organs | 5 (3.4) | 1 (1.5) | 4 (5.1) | 2 (3.4) | 0 (0.0) | 2 (18.2) | 1 (2.4) |
Cardiorespiratory/circulatory organ | 4 (2.7) | 2 (2.9) | 2 (2.5) | 2 (3.4) | 1 (2.5) | 0 (0.0) | 1 (2.4) |
Genitourinary | 3 (2.0) | 1 (1.5) | 2 (2.5) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 1 (2.4) |
Complications of PFS | 1 (0.7) | 1 (1.5) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Othera | 1 (0.7) | 1 (1.5) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
None of the above | 12 (8.2) | 7 (10.3) | 5 (6.3) | 6 (10.2) | 4 (10.0) | 0 (0.0) | 2 (4.8) |
Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | ||||
---|---|---|---|---|---|---|---|
CAPS (n=59) | TRAPS (n=40) | HIDS/MKD (n=12) | FMF (n=42) | ||||
PFS subtype, n (%) | |||||||
CAPS | 54 (36.7) | 23 (33.8) | 31 (39.2) | 54 (91.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
FCAS | 22 (15.0) | 8 (11.8) | 14 (17.7) | 22 (37.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
MWS | 24 (16.3) | 11 (16.2) | 13 (16.5) | 24 (40.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Mixed CAPS phenotype | 8 (5.4) | 4 (5.9) | 4 (5.1) | 8 (13.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
TRAPS | 39 (26.5) | 17 (25.0) | 22 (27.8) | 0 (0.0) | 39 (97.5) | 0 (0.0) | 0 (0.0) |
HIDS/MKD | 10 (6.8) | 6 (8.8) | 4 (5.1) | 0 (0.0) | 0 (0.0) | 10 (90.9) | 0 (0.0) |
FMF | 39 (26.5) | 19 (27.9) | 20 (25.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 39 (92.9) |
Mixed PFSa | 5 (3.4) | 3 (4.4) | 2 (2.5) | 5 (8.5) | 1 (2.5) | 1 (9.1) | 3 (7.1) |
Age at PFS diagnosis, mean (SD) | 16.5 (15.0) | 6.9 (4.0) | 24.8 (16.1) | 17.7 (16.7) | 17.6 (14.7) | 13.9 (15.2) | 13.5 (11.9) |
Time elapsed between initial symptoms and diagnosis, n (%) | |||||||
<6 months | 10 (6.8) | 6 (8.8) | 4 (5.1) | 5 (8.5) | 1 (2.5) | 0 (0.0) | 4 (9.5) |
6–12 months | 50 (34.0) | 27 (39.7) | 23 (29.1) | 24 (40.7) | 14 (35.0) | 1 (9.1) | 11 (26.2) |
1–2 years | 52 (35.4) | 29 (42.6) | 23 (29.1) | 22 (37.3) | 15 (37.5) | 6 (54.5) | 13 (31.0) |
2–5 years | 19 (12.9) | 5 (7.4) | 14 (17.7) | 3 (5.1) | 6 (15.0) | 3 (27.3) | 8 (19.0) |
>5 years | 13 (8.8) | 0 (0.0) | 13 (16.5) | 5 (8.5) | 2 (5.0) | 1 (9.1) | 5 (11.9) |
Unknown | 3 (2.0) | 1 (1.5) | 2 (2.5) | 0 (0.0) | 2 (5.0) | 0 (0.0) | 1 (2.4) |
Primary specialty of physician who has first diagnosed PFS, n (%) | |||||||
Rheumatology | 75 (51.0) | 28 (41.2) | 47 (59.5) | 24 (40.7) | 24 (60.0) | 5 (45.5) | 24 (57.1) |
Immunology | 29 (19.7) | 20 (29.4) | 9 (11.4) | 18 (30.5) | 3 (7.5) | 0 (0.0) | 10 (23.8) |
Internal medicine | 15 (10.2) | 8 (11.8) | 7 (8.9) | 3 (5.1) | 8 (20.0) | 2 (18.2) | 2 (4.8) |
Allergy | 15 (10.2) | 5 (7.4) | 10 (12.7) | 9 (15.3) | 3 (7.5) | 2 (18.2) | 2 (4.8) |
Dermatology | 9 (6.1) | 5 (7.4) | 4 (5.1) | 4 (6.8) | 2 (5.0) | 1 (9.1) | 2 (4.8) |
Otherb | 1 (0.7) | 1 (1.5) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 3 (2.0) | 1 (1.5) | 2 (2.5) | 0 (0.0) | 0 (0.0) | 1 (9.1) | 2 (4.8) |
Methods of diagnosis, n (%) | |||||||
Assessment of clinical manifestations and complications (e.g., recurrent fever) | 128 (87.1) | 59 (86.8) | 69 (87.3) | 51 (86.4) | 35 (87.5) | 7 (63.6) | 39 (92.9) |
Age of onset | 92 (62.6) | 43 (63.2) | 49 (62.0) | 37 (62.7) | 25 (62.5) | 8 (72.7) | 26 (61.9) |
Assessment of family history/ancestry | 84 (57.1) | 43 (63.2) | 41 (51.9) | 38 (64.4) | 21 (52.5) | 6 (54.5) | 22 (52.4) |
Exclusion/rule-out diagnostics (e.g., infection, neoplasms) | 77 (52.4) | 36 (52.9) | 41 (51.9) | 31 (52.5) | 17 (42.5) | 4 (36.4) | 28 (66.7) |
Assessment of triggers (e.g., menstruation, vaccination, stress, cold, infection) | 76 (51.7) | 39 (57.4) | 37 (46.8) | 32 (54.2) | 18 (45.0) | 6 (54.5) | 22 (52.4) |
Genetic tests | 65 (44.2) | 36 (52.9) | 29 (36.7) | 27 (45.8) | 10 (25.0) | 6 (54.5) | 25 (59.5) |
Laboratory assessments (e.g., CRP, ESR, SAA) | 63 (42.9) | 31 (45.6) | 32 (40.5) | 24 (40.7) | 13 (32.5) | 5 (45.5) | 23 (54.8) |
Response to trial therapy | 42 (28.6) | 23 (33.8) | 19 (24.1) | 17 (28.8) | 4 (10.0) | 2 (18.2) | 22 (52.4) |
Otherc | 1 (0.7) | 1 (1.5) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Combination of methods used for diagnosis, n (%) | |||||||
>1 diagnosis method | 128 (87.1) | 63 (92.6) | 65 (82.3) | 52 (88.1) | 33 (82.5) | 9 (81.8) | 38 (90.5) |
>2 diagnosis method | 108 (73.5) | 54 (79.4) | 54 (68.4) | 44 (74.6) | 25 (62.5) | 7 (63.6) | 36 (85.7) |
Diagnoses ruled out prior to the confirmed diagnosis, n (%) | |||||||
Fever of unknown origin | 103 (70.1) | 50 (73.5) | 53 (67.1) | 41 (69.5) | 26 (65.0) | 8 (72.7) | 32 (76.2) |
Urticaria or rash/allergy | 80 (54.4) | 34 (50.0) | 46 (58.2) | 32 (54.2) | 20 (50.0) | 6 (54.5) | 25 (59.5) |
Recurrent infection | 75 (51.0) | 41 (60.3) | 34 (43.0) | 26 (44.1) | 19 (47.5) | 4 (36.4) | 28 (66.7) |
Systemic lupus erythematosus | 36 (24.5) | 18 (26.5) | 18 (22.8) | 13 (22.0) | 9 (22.5) | 2 (18.2) | 12 (28.6) |
Vasculitis (e.g., polyarthritis nodosa, Behcet’s disease) | 47 (32.0) | 22 (32.4) | 25 (31.6) | 20 (33.9) | 10 (25.0) | 4 (36.4) | 14 (33.3) |
Pharyngitis | 43 (29.3) | 19 (27.9) | 24 (30.4) | 22 (37.3) | 9 (22.5) | 2 (18.2) | 12 (28.6) |
Rheumatoid arthritis | 32 (21.8) | 11 (16.2) | 21 (26.6) | 12 (20.3) | 11 (27.5) | 2 (18.2) | 8 (19.0) |
Neoplasms | 35 (23.8) | 17 (25.0) | 18 (22.8) | 15 (25.4) | 9 (22.5) | 1 (9.1) | 10 (23.8) |
Other juvenile idiopathic arthritis | 25 (17.0) | 18 (26.5) | 7 (8.9) | 10 (16.9) | 7 (17.5) | 1 (9.1) | 7 (16.7) |
Inflammatory bowel disease | 21 (14.3) | 9 (13.2) | 12 (15.2) | 7 (11.9) | 3 (7.5) | 4 (36.4) | 7 (16.7) |
PFS subtype other than the final diagnosis | 12 (8.2) | 10 (14.7) | 2 (2.5) | 7 (11.9) | 1 (2.5) | 0 (0.0) | 4 (9.5) |
No rule-out diagnosis | 9 (6.1) | 3 (4.4) | 6 (7.6) | 1 (1.7) | 8 (20.0) | 1 (9.1) | 0 (0.0) |
Otherd | 5 (3.4) | 1 (1.5) | 4 (5.1) | 1 (1.7) | 1 (2.5) | 0 (0.0) | 3 (7.1) |
PFS treatment history prior to canakinumab
Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | ||||
---|---|---|---|---|---|---|---|
CAPS (N=59) | TRAPS (N=40) | HIDS/MKD (N=11) | FMF (N=42) | ||||
Years from first long-term treatment for PFS until canakinumab initiation
| |||||||
Known, n (%) | 94 (63.9) | 46 (67.6) | 48 (60.8) | 39 (66.1) | 24 (60.0) | 4 (36.4) | 30 (71.4) |
Mean (SD) | 2.5 (3.5) | 1.8 (2.4) | 3.1 (4.2) | 2.4 (3.2) | 2.6 (3.7) | 3.8 (3.9) | 2.6 (3.8) |
First long-term treatment for PFS
a
, n (%)
| |||||||
Oral corticosteroids | 62 (42.2) | 29 (42.6) | 33 (41.8) | 22 (37.3) | 21 (52.5) | 5 (45.5) | 18 (42.9) |
Nonsteroidal anti-inflammatory drugs | 61 (41.5) | 32 (47.1) | 29 (36.7) | 25 (42.4) | 16 (40.0) | 4 (36.4) | 18 (42.9) |
Colchicine | 56 (38.1) | 32 (47.1) | 24 (30.4) | 20 (33.9) | 10 (25.0) | 2 (18.2) | 26 (61.9) |
Methotrexate | 32 (31.8) | 6 (8.8) | 26 (32.9) | 9 (15.3) | 13 (32.5) | 3 (27.3) | 7 (16.7) |
Corticosteroid injection | 9 (6.1) | 4 (5.9) | 5 (6.3) | 1 (1.7) | 7 (17.5) | 0 (0.0) | 1 (2.4) |
Thalidomide | 1 (0.7) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 1 (2.5) | 0 (0.0) | 0 (0.0) |
Biologics | |||||||
Anakinra | 26 (17.7) | 16 (23.5) | 10 (12.7) | 14 (23.7) | 4 (10.0) | 3 (27.3) | 8 (19.0) |
Adalimumab | 17 (11.6) | 5 (7.4) | 12 (15.2) | 6 (10.2) | 9 (22.5) | 1 (9.1) | 2 (4.8) |
Canakinumab | 14 (9.5) | 3 (4.4) | 11 (13.9) | 7 (11.9) | 3 (7.5) | 1 (9.1) | 3 (7.1) |
Rituximab | 5 (3.4) | 0 (0.0) | 5 (6.3) | 0 (0.0) | 4 (10.0) | 1 (9.1) | 0 (0.0) |
Etanercept | 4 (2.7) | 2 (2.9) | 2 (2.5) | 2 (3.4) | 1 (2.5) | 0 (0.0) | 1 (2.4) |
Infliximab | 4 (2.7) | 3 (4.4) | 1 (1.3) | 0 (0.0) | 1 (2.5) | 0 (0.0) | 3 (7.1) |
Rilonacept | 2 (1.4) | 2 (2.9) | 0 (0.0) | 2 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Tocilizumab | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 2 (1.4) | 1 (1.5) | 1 (1.3) | 0 (0.0) | 2 (5.0) | 0 (0.0) | 0 (0.0) |
Treatments directly preceding canakinumab initiation, n (%) | Overall (N=133) | Children (N=65) | Adults (N=68) | PFS subtypes | |||
---|---|---|---|---|---|---|---|
CAPS (n=52) | TRAPS (n=37) | HIDS/MKD (n=10) | FMF (n=39) | ||||
Nonsteroidal anti-inflammatory drugs | 37 (27.8) | 25 (38.5) | 12 (17.6) | 19 (36.5) | 7 (18.9) | 4 (40.0) | 9 (23.1) |
Colchicine | 29 (21.8) | 13 (20.0) | 16 (23.5) | 10 (19.2) | 3 (8.1) | 2 (20.0) | 14 (35.9) |
Oral corticosteroids | 23 (17.3) | 13 (20.0) | 10 (14.7) | 8 (15.4) | 7 (18.9) | 1 (10.0) | 8 (20.5) |
Methotrexate | 19 (14.3) | 3 (4.6) | 16 (23.5) | 5 (9.6) | 8 (21.6) | 0 (0.0) | 6 (15.4) |
Corticosteroid injection | 7 (5.3) | 3 (4.6) | 4 (5.9) | 0 (0.0) | 6 (16.2) | 0 (0.0) | 1 (2.6) |
Thalidomide | 1 (0.8) | 1 (1.5) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Biologics | |||||||
Anakinra | 32 (24.1) | 22 (33.8) | 10 (14.7) | 17 (32.7) | 6 (16.2) | 3 (30.0) | 9 (23.1) |
Adalimumab | 12 (9.0) | 3 (4.6) | 9 (13.2) | 4 (7.7) | 5 (13.5) | 1 (10.0) | 3 (7.7) |
Etanercept | 9 (6.8) | 4 (6.2) | 5 (7.4) | 3 (5.8) | 3 (8.1) | 1 (10.0) | 2 (5.1) |
Infliximab | 6 (4.5) | 4 (6.2) | 2 (2.9) | 1 (1.9) | 3 (8.1) | 1 (10.0) | 1 (2.6) |
Rilonacept | 6 (4.5) | 2 (3.1) | 4 (5.9) | 5 (9.6) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
Rituximab | 2 (1.5) | 0 (0.0) | 2 (2.9) | 1 (1.9) | 0 (0.0) | 1 (10.0) | 0 (0.0) |
Tocilizumab | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Unknown | 2 (1.5) | 0 (0.0) | 2 (2.9) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 1 (2.6) |
Reasons for discontinuation of treatments prior to canakinumab
Canakinumab prescribing patterns
Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | ||||
---|---|---|---|---|---|---|---|
CAPS (N=59) | TRAPS (N=40) | HIDS/MKD (N=11) | FMF (N=42) | ||||
Age when first prescribed canakinumab (years), mean (SD) | 20.7 (15.9) | 9.1 (4.3) | 30.7 (15.5) | 22.9 (17.8) | 20.4 (14.6) | 19.8 (19.4) | 17.4 (12.3) |
Year of canakinumab initiation, n (%) | |||||||
2016 | 8 (5.4) | 2 (2.9) | 6 (7.6) | 4 (6.8) | 1 (2.5) | 0 (0.0) | 3 (7.1) |
2017 | 58 (39.5) | 27 (39.7) | 31 (39.2) | 26 (44.1) | 15 (37.5) | 5 (45.5) | 15 (35.7) |
2018 | 81 (55.1) | 39 (57.4) | 42 (53.2) | 29 (49.2) | 24 (60.0) | 6 (54.5) | 24 (57.1) |
Canakinumab initial dose (reported by physician as mg/kg or calculated mg/kg when weight was available), mean (SD) | 2.8 (1.8) [N=144] | 3.3 (2.2) [N=67] | 2.3 (1.1) [N=77] | 3.0 (2.2) [N=57] | 2.3 (0.7) [N=40] | 2.4 (1.3) [N=10] | 3.0 (1.8) [N=41] |
Initial dose among physicians who reported mg/kg, mean (SD) | 2.9 (1.9) [N=67] | 2.9 (2.0) [N=47] | 2.9 (1.5) [N=20] | 3.3 (2.3) [N=27] | 2.0 (0.0) [N=12] | 2.2 (0.4) [N=6] | 3.0 (1.7) [N=24] |
Initial dose among physicians who reported mg | N=80 | N=21 | N=59 | N=32 | N=28 | N=5 | N=18 |
Mean (SD) | 134.2 (46.9) | 123.3 (38.1) | 138.1 (49.4) | 138.7 (54.0) | 134.8 (39.3) | 112.4 (60.2) | 133.9 (38.5) |
Median (Q1, Q3) | 150.0 (150.0, 150.0) | 150.0 (100.0, 150.0) | 150.0 (150.0, 150.0) | 150.0 (150.0, 150.0) | 150.0 (150.0, 150.0) | 150.0 (100.0, 150.0) | 150.0 (150.0, 150.0) |
Initial frequency, n (%) | |||||||
Every 4 weeks | 73 (49.7) | 36 (52.9) | 37 (46.8) | 19 (32.2) | 23 (57.5) | 6 (54.5) | 26 (61.9) |
Every 8 weeks | 74 (50.3) | 32 (47.1) | 42 (53.2) | 40 (67.8) | 17 (42.5) | 5 (45.5) | 16 (38.1) |
Received concomitant treatment with another long- or short-term PFS medication (including biologics), n (%) | |||||||
Yes | 67 (45.6) | 29 (42.6) | 38 (48.1) | 26 (44.1) | 20 (50.0) | 5 (45.5) | 18 (42.9) |
No | 80 (54.4) | 39 (57.4) | 41 (51.9) | 33 (55.9) | 20 (50.0) | 6 (54.5) | 24 (57.1) |